1. RedHill supports an H. Pylori CME program to improve clinical education. 2. Talicia is the leading therapy for H. pylori, addressing antibiotic resistance. 3. The CME program targets healthcare professionals for better H. pylori management. 4. H. pylori affects nearly 50% of the global population and is a carcinogen. 5. RedHill will exhibit at Digestive Diseases Week in San Diego.
The CME program highlights RedHill's commitment to its leading therapy, Talicia. Increased awareness of H. pylori management can boost Talicia prescriptions.
The CME program underlines Talicia's role in H. pylori treatment, likely resulting in higher medical usage and prescriptions.
The educational initiative may take time to translate into increased market share and awareness, enhancing Talicia's long-term growth potential.
RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes.
The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD, and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting.
H. pylori is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease. With almost half the global population infected by H. pylori, its treatment represents a billion-dollar market opportunity.
Listed by the American College of Gastroenterology (ACG) Clinical Guideline as a first-line option, Talicia® is the leading branded H. pylori therapy prescribed by U.S. gastroenterologists and is the only FDA-approved all-in-one, low-dose rifabutin-based therapy designed to address H. pylori resistance to other antibiotics.
RALEIGH, N.C., May 2, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its support for an independent medical education grant that includes a new two-part H. pylori CME program developed by Medscape. The first part of the program, a livestreamed event entitled "Let's Get Social About H. pylori Management," will take place on May 6 during a major gastroenterology meeting.
RedHill will also be attending Digestive Diseases Week (DDW) in San Diego and will be available at booth 5312.
Kel Sheldon, PhD, BCMAS, RedHill's Director, Medical Affairs, said: "We are proud to announce that RedHill is supporting a Medscape CME educational program to help meet the need for healthcare professional education on H. pylori infection and treatment options. RedHill believes in the critical need to effectively treat H. pylori at the first attempt amid increasing global concern of rising antibiotic resistance..."
An overview of the event: A 30-minute expert panel livestream (0.5 CME Credits) on Medscape's social media channels (YouTube, LinkedIn, Facebook), focusing on antibiotic resistance, guideline-directed therapies, and patient adherence in H. pylori management. The event will remain available on-demand post-livestream to support gastroenterology professionals unable to attend the live event.
Expert Roundtable: Overcoming Challenges in H. pylori Diagnosis and Treatment.
H. pylori infection affects around 50% of the global adult population and is classified by the WHO as a Group 1 carcinogen and the strongest known risk factor for gastric cancer.
Talicia, approved by the FDA for the treatment of H. pylori infection in adults, is a novel combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole)...
Talicia is a three-drug combination indicated for the treatment of Helicobacter pylori infection in adults. To reduce the development of drug-resistant bacteria...
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases...
This press release contains forward-looking statements which may discuss investment opportunities, stock analysis, and market trends...